uniQure (NASDAQ:QURE) Receives Consensus Recommendation of “Buy” from Analysts

Shares of uniQure (NASDAQ:QURE) have earned a consensus recommendation of “Buy” from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $40.00.

A number of analysts have commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Cantor Fitzgerald increased their price target on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. Leerink Partners lifted their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Finally, HC Wainwright increased their price objective on shares of uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, January 27th.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.74% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 969 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of uniQure during the fourth quarter worth about $88,000. Geode Capital Management LLC raised its position in shares of uniQure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after purchasing an additional 6,362 shares during the last quarter. RTW Investments LP purchased a new position in uniQure in the 3rd quarter valued at about $49,000. Finally, Atria Investments Inc acquired a new stake in uniQure in the 3rd quarter worth about $53,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Trading Down 9.7 %

NASDAQ:QURE opened at $14.63 on Monday. The company has a market capitalization of $713.07 million, a P/E ratio of -2.95 and a beta of 0.38. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The firm has a fifty day simple moving average of $14.87 and a 200-day simple moving average of $9.25.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.